Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TAPBP (ImmuneEditome ID:6892)

1. Gene summary of enriched editing regions for TAPBP

Gene summary

Gene information	Gene symbol	TAPBP
	Gene ID	6892
	GeneSynonyms	NGS17\|TAPA\|TPN\|TPSN
	GeneCytomap	6p21.32
	GeneType	protein-coding
	GeneDescription	tapasin\|NGS-17\|TAP binding protein (tapasin)\|TAP-associated protein
	GeneModificationdate	20230518
	UniprotID	A0A0A0MSV9;A0A0A0MT98;Q6P1N7;O15533;A0A024RCT1;A0A0G2JH37;A2AB90;A0A0G2JJI5;A0A0G2JKZ1;A0A140T9B2
	PubMed ID	27068360

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr6:33301439-33303442:-	ENST00000434618.5	ENSG00000231925.10	TAPBP	exonic	AluSq2,AluSx,AluJb,MER33,Tigger4,Tigger4b,AluSx1,L2b,Tigger4a,(TTTGT)n	chr6:33301439-33303442:-.alignment
chr6:33301439-33303442:-	ENST00000475304.4	ENSG00000231925.10	TAPBP	exonic	AluSq2,AluSx,AluJb,MER33,Tigger4,Tigger4b,AluSx1,L2b,Tigger4a,(TTTGT)n	chr6:33301439-33303442:-.alignment
chr6:33301439-33303442:-	ENST00000489157.4	ENSG00000231925.10	TAPBP	exonic	AluSq2,AluSx,AluJb,MER33,Tigger4,Tigger4b,AluSx1,L2b,Tigger4a,(TTTGT)n	chr6:33301439-33303442:-.alignment
chr6:33306726-33310367:-	ENST00000475304.4	ENSG00000231925.10	TAPBP	exonic	FLAM_C,AluJo,AluSq2,MER30,MIR,AluSp,AluSx1	chr6:33306726-33310367:-.alignment

Top

2. Tumor-specific enriched editing regions for TAPBP

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr6:33301439-33303442:-	BRCA	EER	4.8908e-07
ENSG00000231925.10,TAPBP	BRCA	EAG	3.9126e-05
chr6:33301439-33303442:-	LUSC	EER	4.0995e-03
ENSG00000231925.10,TAPBP	LUSC	EAG	4.1850e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000231925.10,TAPBP	ACC	Path	EAG	1.9915e-02	2.4346e-02	0.3247

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000231925.10,TAPBP	COAD	EAG	1.2488e-02	3.9903e-02	6.1243e-02
chr6:33306726-33310367:-	ESCA	EER	1.9131e-02	1.6383e-02	9.3493e+01
chr6:33301439-33303442:-	HNSC	EER	3.0738e-02	9.0775e-03	1.6251e+02

Top

3. Enriched editing regions and immune related genes for TAPBP

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr6:33306726-33310367:-

ESCA

EER

ENSG00000168872,DDX19A

0.3521

1.1498e-02

1.3076e-06

0.4186

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_E2F_TARGETS

chr6:33306726-33310367:-

ESCA

EER

ENSG00000169439,SDC2

0.3024

4.0809e-02

6.7119e-08

0.4618

Macrophages_M2

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results

Top

4. Enriched editing regions and immune related splicing for TAPBP

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for TAPBP

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000231925.10,TAPBP	ACC	EAG	Neutrophils	1.5854e-03	0.4394
chr6:33301439-33303442:-	BLCA	EER	Monocytes	2.7749e-02	-0.1698
ENSG00000231925.10,TAPBP	BLCA	EAG	Monocytes	3.4006e-02	-0.1613
ENSG00000231925.10,TAPBP	CESC	EAG	Monocytes	4.6721e-02	-0.1590
chr6:33301439-33303442:-	CHOL	EER	Neutrophils	2.3319e-03	0.5808
ENSG00000231925.10,TAPBP	CHOL	EAG	Neutrophils	2.1998e-03	0.5637
chr6:33301439-33303442:-	COAD	EER	Dendritic_cells_activated	1.2131e-02	0.2004
chr6:33301439-33303442:-	ESCA	EER	Dendritic_cells_activated	3.5026e-02	0.1734
chr6:33306726-33310367:-	ESCA	EER	T_cells_regulatory_(Tregs)	6.1411e-03	-0.2448
ENSG00000231925.10,TAPBP	GBM	EAG	T_cells_gamma_delta	3.3272e-03	0.2482
ENSG00000231925.10,TAPBP	HNSC	EAG	Macrophages_M1	1.5648e-02	0.1990
ENSG00000231925.10,TAPBP	KIRC	EAG	Dendritic_cells_activated	2.9935e-02	0.1280
chr6:33306726-33310367:-	LAML	EER	Mast_cells_resting	2.3526e-03	-0.3886
ENSG00000231925.10,TAPBP	LAML	EAG	Mast_cells_activated	7.1279e-03	0.3167
chr6:33301439-33303442:-	LGG	EER	B_cells_naive	3.1021e-02	0.1792
ENSG00000231925.10,TAPBP	LGG	EAG	T_cells_regulatory_(Tregs)	2.4359e-02	0.1557
chr6:33301439-33303442:-	LIHC	EER	T_cells_CD4_memory_activated	2.1855e-02	-0.2415
ENSG00000231925.10,TAPBP	LIHC	EAG	Macrophages_M1	2.7811e-02	-0.1992
chr6:33301439-33303442:-	LUSC	EER	Plasma_cells	1.7026e-02	-0.1661
ENSG00000231925.10,TAPBP	LUSC	EAG	T_cells_follicular_helper	1.4871e-02	-0.1667
chr6:33301439-33303442:-	MESO	EER	Macrophages_M0	3.2285e-02	0.2945
chr6:33301439-33303442:-	OV	EER	T_cells_gamma_delta	2.4316e-07	0.3136
chr6:33306726-33310367:-	OV	EER	Dendritic_cells_resting	9.7525e-03	0.2193
ENSG00000231925.10,TAPBP	OV	EAG	T_cells_gamma_delta	6.0146e-05	0.2421
chr6:33301439-33303442:-	PCPG	EER	Macrophages_M1	4.2411e-04	0.3275
ENSG00000231925.10,TAPBP	PCPG	EAG	T_cells_gamma_delta	3.1960e-03	0.2649
chr6:33301439-33303442:-	PRAD	EER	T_cells_CD8	3.4366e-03	0.1545
ENSG00000231925.10,TAPBP	PRAD	EAG	T_cells_CD8	3.6163e-03	0.1524
chr6:33301439-33303442:-	READ	EER	B_cells_memory	1.5994e-02	0.3206
ENSG00000231925.10,TAPBP	READ	EAG	B_cells_memory	1.7863e-02	0.3127
chr6:33301439-33303442:-	SARC	EER	Macrophages_M0	3.3149e-02	-0.2071
ENSG00000231925.10,TAPBP	SARC	EAG	Macrophages_M0	4.6872e-02	-0.1788
chr6:33301439-33303442:-	SKCM	EER	Neutrophils	1.1539e-02	-0.2145
ENSG00000231925.10,TAPBP	SKCM	EAG	Macrophages_M1	2.8462e-02	0.1783
chr6:33306726-33310367:-	STAD	EER	T_cells_regulatory_(Tregs)	3.2777e-04	-0.2174
chr6:33301439-33303442:-	THCA	EER	Dendritic_cells_resting	2.6616e-03	0.1812
ENSG00000231925.10,TAPBP	THCA	EAG	Dendritic_cells_resting	1.0483e-03	0.1938
chr6:33301439-33303442:-	THYM	EER	Monocytes	1.1625e-02	0.3000
ENSG00000231925.10,TAPBP	THYM	EAG	Monocytes	1.2465e-02	0.2951
chr6:33301439-33303442:-	UCEC	EER	T_cells_CD4_memory_resting	1.3139e-02	-0.2779
ENSG00000231925.10,TAPBP	UCEC	EAG	B_cells_naive	4.5157e-02	0.2192

Top

6. Enriched editing regions and immune gene sets for TAPBP

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr6:33301439-33303442:-	LGG	EER	1.3651e-02	0.2044	2.8688e-02	0.1817	2.4252e-02	0.1871	4.4020e-02	0.1675
chr6:33306726-33310367:-	STAD	EER	4.3525e-02	0.1232	3.5422e-02	0.1283	3.0891e-02	0.1316	5.3033e-06	0.2735

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000231925.10,TAPBP	ACC	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.4622e-02	0.3468
chr6:33301439-33303442:-	BLCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.3893e-02	-0.1557
ENSG00000231925.10,TAPBP	BLCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.2890e-02	-0.1887
ENSG00000231925.10,TAPBP	BRCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.9489e-02	0.0768
chr6:33301439-33303442:-	BRCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	6.0490e-06	0.1624
chr6:33301439-33303442:-	CESC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.4696e-03	-0.2470
ENSG00000231925.10,TAPBP	CESC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.6972e-02	-0.1903
ENSG00000231925.10,TAPBP	COAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.0654e-02	-0.1704
chr6:33306726-33310367:-	ESCA	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	1.9509e-03	0.2756
ENSG00000231925.10,TAPBP	GBM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.8157e-02	-0.2009
ENSG00000231925.10,TAPBP	HNSC	GSVA_HALLMARK_PEROXISOME	EAG	2.4674e-04	0.2980
chr6:33301439-33303442:-	HNSC	GSVA_HALLMARK_GLYCOLYSIS	EER	8.5365e-04	0.2817
chr6:33301439-33303442:-	KIRC	GSVA_HALLMARK_HEME_METABOLISM	EER	1.3278e-07	0.3063
ENSG00000231925.10,TAPBP	KIRC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	1.1363e-06	0.2821
ENSG00000231925.10,TAPBP	KIRP	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.2306e-03	0.2557
chr6:33301439-33303442:-	KIRP	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	8.2595e-04	0.2651
chr6:33306726-33310367:-	LAML	GSVA_HALLMARK_MYC_TARGETS_V1	EER	2.0947e-03	-0.3927
ENSG00000231925.10,TAPBP	LAML	GSVA_HALLMARK_SPERMATOGENESIS	EAG	6.2763e-03	-0.3214
ENSG00000231925.10,TAPBP	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	5.4388e-03	-0.1916
chr6:33301439-33303442:-	LGG	GSVA_HALLMARK_GLYCOLYSIS	EER	5.2491e-03	0.2307
ENSG00000231925.10,TAPBP	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.6945e-02	-0.2159
chr6:33301439-33303442:-	LIHC	GSVA_HALLMARK_HEME_METABOLISM	EER	2.6426e-02	0.2340
ENSG00000231925.10,TAPBP	LUAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	9.2929e-03	0.1439
chr6:33301439-33303442:-	LUAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	5.0347e-05	0.2296
ENSG00000231925.10,TAPBP	LUSC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	9.0968e-03	0.1783
chr6:33301439-33303442:-	LUSC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	4.1652e-03	0.1988
chr6:33301439-33303442:-	MESO	GSVA_HALLMARK_MYC_TARGETS_V1	EER	3.2342e-02	0.2944
chr6:33306726-33310367:-	OV	GSVA_HALLMARK_NOTCH_SIGNALING	EER	3.3698e-04	0.3008
ENSG00000231925.10,TAPBP	OV	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	1.2877e-02	-0.1515
chr6:33301439-33303442:-	OV	GSVA_HALLMARK_MYC_TARGETS_V2	EER	5.4093e-03	0.1720
ENSG00000231925.10,TAPBP	PAAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.1665e-02	-0.2318
chr6:33301439-33303442:-	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.4178e-03	0.2839
ENSG00000231925.10,TAPBP	PCPG	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.3058e-02	-0.2242
chr6:33301439-33303442:-	PRAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	6.8547e-03	-0.1429
ENSG00000231925.10,TAPBP	PRAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	8.8446e-03	-0.1372
chr6:33301439-33303442:-	READ	GSVA_HALLMARK_HYPOXIA	EER	6.1990e-03	0.3614
ENSG00000231925.10,TAPBP	READ	GSVA_HALLMARK_HYPOXIA	EAG	2.8678e-02	0.2900
ENSG00000231925.10,TAPBP	SARC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	2.1068e-02	0.2070
chr6:33301439-33303442:-	SARC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	2.5118e-03	0.2906
ENSG00000231925.10,TAPBP	SKCM	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.1816e-04	0.2891
chr6:33301439-33303442:-	SKCM	GSVA_HALLMARK_PEROXISOME	EER	2.4705e-04	0.3072
ENSG00000231925.10,TAPBP	STAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.3824e-02	0.1224
chr6:33306726-33310367:-	STAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	7.7056e-07	0.2960
chr6:33301439-33303442:-	STAD	GSVA_HALLMARK_COAGULATION	EER	3.9152e-02	0.1156

Top

7. Enriched editing regions and drugs for TAPBP

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000231925.10,TAPBP	ACC	Gemcitabine	EAG	1.9033e-04	-0.5086
chr6:33301439-33303442:-	BLCA	CCT007093	EER	1.8974e-03	0.2380
ENSG00000231925.10,TAPBP	BLCA	Gemcitabine	EAG	3.4024e-04	-0.2693
ENSG00000231925.10,TAPBP	BRCA	Embelin	EAG	3.0482e-02	-0.0764
chr6:33301439-33303442:-	BRCA	Lapatinib	EER	1.3063e-02	-0.0899
chr6:33301439-33303442:-	CESC	GW843682X	EER	1.2899e-02	-0.2040
ENSG00000231925.10,TAPBP	CESC	GW843682X	EAG	2.1924e-02	-0.1828
ENSG00000231925.10,TAPBP	CHOL	FH535	EAG	2.3968e-02	0.4333
chr6:33301439-33303442:-	CHOL	BIBW2992	EER	1.3897e-02	-0.4855
ENSG00000231925.10,TAPBP	DLBC	CGP.60474	EAG	1.0137e-02	-0.4070
chr6:33301439-33303442:-	ESCA	AUY922	EER	1.1193e-03	0.2653
chr6:33306726-33310367:-	ESCA	Axitinib	EER	1.0083e-03	-0.2918
ENSG00000231925.10,TAPBP	ESCA	Cisplatin	EAG	2.1130e-02	-0.1875
ENSG00000231925.10,TAPBP	GBM	Gemcitabine	EAG	6.4755e-04	-0.2868
ENSG00000231925.10,TAPBP	HNSC	ATRA	EAG	1.2174e-02	-0.2063
chr6:33301439-33303442:-	HNSC	Bleomycin	EER	1.3471e-02	0.2107
chr6:33301439-33303442:-	KIRC	AG.014699	EER	1.3165e-02	0.1467
ENSG00000231925.10,TAPBP	KIRC	Gemcitabine	EAG	1.1439e-02	-0.1488
ENSG00000231925.10,TAPBP	KIRP	JW.7.52.1	EAG	3.6448e-02	-0.1671
chr6:33301439-33303442:-	KIRP	Erlotinib	EER	4.3068e-03	-0.2274
chr6:33306726-33310367:-	LAML	LFM.A13	EER	1.7979e-03	-0.3980
ENSG00000231925.10,TAPBP	LAML	Bicalutamide	EAG	4.4247e-03	-0.3339
chr6:33301439-33303442:-	LGG	BI.D1870	EER	1.0827e-04	-0.3159
ENSG00000231925.10,TAPBP	LGG	BI.D1870	EAG	2.5725e-04	-0.2503
ENSG00000231925.10,TAPBP	LIHC	JNK.9L	EAG	3.8104e-04	0.3166
chr6:33301439-33303442:-	LIHC	BMS.536924	EER	1.0767e-02	0.2706
ENSG00000231925.10,TAPBP	LUAD	Lapatinib	EAG	1.0033e-03	-0.1814
chr6:33301439-33303442:-	LUAD	Lapatinib	EER	1.5352e-04	-0.2147
ENSG00000231925.10,TAPBP	LUSC	EHT.1864	EAG	1.0690e-02	0.1746
chr6:33301439-33303442:-	LUSC	Cytarabine	EER	8.6904e-03	0.1824
chr6:33301439-33303442:-	MESO	AMG.706	EER	2.3659e-02	0.3105
ENSG00000231925.10,TAPBP	MESO	AMG.706	EAG	4.3843e-02	0.2754
chr6:33301439-33303442:-	OV	Cyclopamine	EER	2.4485e-05	-0.2590
chr6:33306726-33310367:-	OV	Bicalutamide	EER	1.4243e-02	-0.2083
ENSG00000231925.10,TAPBP	OV	AICAR	EAG	4.7149e-03	0.1718
ENSG00000231925.10,TAPBP	PAAD	ABT.263	EAG	2.5905e-02	-0.2274
chr6:33301439-33303442:-	PAAD	Camptothecin	EER	1.0513e-02	-0.2641
ENSG00000231925.10,TAPBP	PCPG	AMG.706	EAG	3.2951e-02	-0.1933
chr6:33301439-33303442:-	PRAD	AICAR	EER	3.3839e-03	-0.1547
ENSG00000231925.10,TAPBP	PRAD	AICAR	EAG	2.9599e-03	-0.1556
ENSG00000231925.10,TAPBP	READ	AZD8055	EAG	2.3181e-02	-0.3004
chr6:33301439-33303442:-	READ	AZD8055	EER	3.9441e-02	-0.2761
chr6:33301439-33303442:-	SARC	CMK	EER	4.6301e-03	0.2730
ENSG00000231925.10,TAPBP	SARC	Gefitinib	EAG	7.0745e-03	-0.2407
chr6:33301439-33303442:-	SKCM	BMS.509744	EER	7.0231e-04	0.2851
ENSG00000231925.10,TAPBP	SKCM	BMS.509744	EAG	1.1486e-03	0.2621
chr6:33306726-33310367:-	STAD	Bicalutamide	EER	6.9946e-04	-0.2054
chr6:33301439-33303442:-	STAD	Camptothecin	EER	3.5047e-02	-0.1181
ENSG00000231925.10,TAPBP	STAD	FH535	EAG	1.6290e-02	0.1300
chr6:33301439-33303442:-	THYM	BX.795	EER	4.4950e-02	-0.2405
ENSG00000231925.10,TAPBP	THYM	Axitinib	EAG	4.2657e-02	-0.2413
chr6:33301439-33303442:-	UCEC	KU.55933	EER	1.6745e-02	-0.2685
ENSG00000231925.10,TAPBP	UCEC	AMG.706	EAG	2.2211e-02	-0.2493

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType